Cedars-Sinai Heart Institute and Department of Imaging, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Atherosclerosis. 2012 Nov;225(1):148-53. doi: 10.1016/j.atherosclerosis.2012.08.002. Epub 2012 Aug 24.
The effect of statins on coronary artery plaque features beyond stenosis severity is not known. Coronary CT angiography (CCTA) is a novel non-invasive method that permits direct visualization of coronary atherosclerotic features, including plaque composition. We evaluated the association of statin use to coronary plaque composition type in patients without known coronary artery disease (CAD) undergoing CCTA.
From consecutive individuals, we identified 6673 individuals (2413 on statin therapy and 4260 not on statin therapy) with no known CAD and available statin use status. We studied the relationship between statin use and the presence and extent of specific plaque composition types, which was graded as non-calcified (NCP), mixed (MP), or calcified (CP) plaque.
The mean age was 59 ± 11 (55% male). Compared to the individuals not taking statins, those taking statins had higher prevalence of risk factors and obstructive CAD. In multivariable analyses, statin use was associated with increased the presence of MP [odds ratio (OR) 1.46, 95% confidence interval (CI) 1.27-1.68), p < 0.001] and CP (OR 1.54, 95% CI 1.36-1.74, p < 0.001), but not NCP (OR 1.11, 95% CI 0.96-1.29, p = 0.1). Further, in multivariable analyses, statin use was associated with increasing numbers of coronary segments possessing MP (OR 1.52, 95% CI 1.34-1.73, p < 0.001) and CP (OR 1.52, 95% CI 1.36-1.70, p < 0.001), but not coronary segments with NCP (OR 1.09, 95% CI 0.94-1.25, p = 0.2).
Statin use is associated with an increased prevalence and extent of coronary plaques possessing calcium. The longitudinal effect of statins on coronary plaque composition warrants further investigation.
他汀类药物对狭窄程度以外的冠状动脉斑块特征的影响尚不清楚。冠状动脉 CT 血管造影(CCTA)是一种新的非侵入性方法,可以直接观察冠状动脉粥样硬化特征,包括斑块成分。我们评估了他汀类药物在接受 CCTA 的无已知冠状动脉疾病(CAD)患者中的冠状动脉斑块成分类型的相关性。
我们从连续个体中确定了 6673 名(2413 名接受他汀类药物治疗,4260 名未接受他汀类药物治疗)无已知 CAD 且可用他汀类药物使用情况的个体。我们研究了他汀类药物使用与特定斑块成分类型的存在和程度之间的关系,这些成分类型被评为非钙化(NCP)、混合(MP)或钙化(CP)斑块。
平均年龄为 59 ± 11 岁(55%为男性)。与未服用他汀类药物的个体相比,服用他汀类药物的个体具有更高的危险因素和阻塞性 CAD 患病率。多变量分析显示,他汀类药物的使用与 MP 的存在呈正相关[比值比(OR)1.46,95%置信区间(CI)1.27-1.68),p < 0.001]和 CP(OR 1.54,95%CI 1.36-1.74,p < 0.001),但与 NCP 无关(OR 1.11,95%CI 0.96-1.29,p = 0.1)。此外,多变量分析显示,他汀类药物的使用与具有 MP(OR 1.52,95%CI 1.34-1.73,p < 0.001)和 CP(OR 1.52,95%CI 1.36-1.70,p < 0.001)的冠状动脉节段数量增加相关,但与 NCP 无关(OR 1.09,95%CI 0.94-1.25,p = 0.2)。
他汀类药物的使用与钙含量增加的冠状动脉斑块的患病率和程度增加有关。他汀类药物对冠状动脉斑块成分的纵向影响值得进一步研究。